Reuters logo
BRIEF-Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS
November 6, 2017 / 12:12 PM / 18 days ago

BRIEF-Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS

Nov 6 (Reuters) - Flex Pharma Inc

* Flex Pharma reports positive topline data from exploratory phase 2 trial of FLX-787 in ALS

* Flex Pharma - ‍data from exploratory phase 2 trial of FLX-787 showed statistically significant reduction in cramp-associated pain intensity & stiffness​

* Flex Pharma Inc - ‍FLX-787 was generally well tolerated​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below